Riociguat in diffuse cutaneous systemic sclerosis (dcSSc)

• Research type

  Research Study

• Full title

  A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

• IRAS ID

  161274

• Contact name

  Christopher Denton

• Contact email

  c.denton@ucl.ac.uk

• Eudract number

  2014-001353-16

• Duration of Study in the UK

  8 years, 5 months, 20 days

• Research summary

  To investigate whether it is safe and beneficial to treat patients suffering from diffuse systemic sclerosis (dcSSc) with Riociguat.

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  14/LO/2037

• Date of REC Opinion

  15 Dec 2014

• REC opinion

  Further Information Favourable Opinion